Kayo Takamatsu-Yukawa

Kayo Takamatsu-Yukawa

Auto-generated profile, based on publicly available information

Kayo Takamatsu-Yukawa

Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2022 in Cell Reports
Verified
Journal Article
Open access
ZRZhi Ruan
Zhi Ruan
KTKayo Takamatsu-Yukawa
Kayo Takamatsu-Yukawa
YWYuzhi Wang
Yuzhi Wang
MUMargaret L. Ushman
Margaret L. Ushman
ALAdam Thomas Labadorf
Adam Thomas Labadorf
TITsuneya Ikezu
Tsuneya Ikezu
Activated microglia release extracellular vesicles (EVs) as modulators of brain homeostasis and innate immunity. However, the molecules critical for regulating EV production from microglia are poorly understood. Here we establish a murine microglial cell model to monitor EV secretion by measuring the fluorescence signal of tdTomato, which is linked to tetraspanin CD63. Stimulation of tdTomato+ cells with ATP induces rapid secretion of EVs and a reduction in cellular tdTomato intensity, reflecting EV secretion. We generate a GFP+ tdTomato+ cell library expressing TurboGFP and barcoded short hairpin RNAs for genome-wide screening using next-generation sequencing. We identify Mcfd2, Sepp1, and Sdc1 as critical regulators of ATP-induced EV secretion from murine microglia. Small interfering RNA (siRNA-based) silencing of each of these genes suppresses lipopolysaccharide- and ATP-induced inflammasome activation, as determined by interleukin-1β release from primary cultured murine microglia. These molecules are critical for microglial EV secretion and are potential therapeutic targets for neuroinflammatory disorders.

1 April 2021 in iScience
Verified
Journal Article
Open access
MWMitsuo Wada
Mitsuo Wada
KYKayo Yukawa
Kayo Yukawa
HOHiroyuki Ogasawara
Hiroyuki Ogasawara
KSKoichi Suzawa
Koichi Suzawa
TMTatsuya Maekawa
Tatsuya Maekawa
Takashi MikiTakashi Miki
Takashi Miki
Gpr52 is an orphan G-protein-coupled receptor of unknown physiological function. We found that Gpr52-deficient (Gpr52−/−) mice exhibit leanness associated with reduced liver weight, decreased hepatic de novo lipogenesis, and enhanced insulin sensitivity. Treatment of the hepatoma cell line HepG2 cells with c11, the synthetic GPR52 agonist, increased fatty acid biosynthesis, and GPR52 knockdown (KD) abolished the lipogenic action of c11. In addition, c11 induced the expressions of lipogenic enzymes (SCD1 and ELOVL6), whereas these inductions were attenuated by GPR52-KD. In contrast, cholesterol biosynthesis was not increased by c11, but its basal level was significantly suppressed by GPR52-KD. High-fat diet (HFD)-induced increase in hepatic expression of Pparg2 and its targets (Scd1 and Elovl6) was absent in Gpr52−/− mice with alleviated hepatosteatosis. Our present study showed that hepatic GPR52 promotes the biosynthesis of fatty acid and cholesterol in a ligand-dependent and a constitutive manner, respectively, and Gpr52 participates in HFD-induced fatty acid synthesis in liver.